Prime Medicine, Inc. (PRME)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.67-1.61%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Prime Medicine, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	6.57M
EPS	—	-0.226
Annual ending 2026-12-31
Revenue	—	9.23M
EPS	—	-0.965
Annual ending 2027-12-31
Revenue	—	11.04M
EPS	—	-0.925

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Fund operations into 2027 with current cash	It aims to fund operations into 2027 with current cash.	Intact	cash reserves fall below operating expense needs before end of 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce losses and improve EPS trajectory	A supporting condition in Prime Medicine, Inc.'s published investment case. The stated target is EPS loss narrows to better than -$0.84 by FY27.	Intact	EPS loss worsens beyond -$0.99 in FY26 or fails to improve in FY27	Diluted EPS: $-0.24 per share FY2026-Q2; GAAP. Published target: EPS loss narrows to better than -$0.84 by FY27. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-0.24 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 124ec75f-6993-434a-ab81-1fd2f10e2385. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance Prime Editing pipeline targeting genetic disorders and cancers	Prime Medicine leads in precise gene editing technology.	Improving	significant delays or failures in key clinical programs	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.92

$-0.84 → $-0.92 · observed estimates

FY2027 revenue$0.01B

$0.02B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.84	$18,388,160	10 / 11
2026-07-25	$-0.84	$18,388,160	10 / 11
2026-07-26	$-0.84	$18,388,160	10 / 11
2026-07-27	$-0.84	$18,388,160	10 / 11
2026-07-28	$-0.84	$18,388,160	10 / 11
2026-07-29	$-0.88	$21,022,484	8 / 8
2026-07-30	$-0.84	$18,388,160	10 / 11
2026-07-31	$-0.88	$21,022,484	8 / 8
2026-08-01	$-0.88	$21,022,484	8 / 8
2026-08-02	$-0.88	$21,022,484	8 / 8
2026-08-03	$-0.88	$21,022,484	8 / 8
2026-08-04	$-0.84	$18,388,160	10 / 11
2026-08-05	$-0.84	$18,388,160	10 / 11
2026-08-06	$-0.88	$21,022,484	8 / 8
2026-08-07	$-0.88	$21,022,484	8 / 8
2026-08-08	$-0.91	$8,049,400	9 / 7
2026-08-09	$-0.91	$8,049,400	9 / 7
2026-08-10	$-0.91	$8,049,400	9 / 7
2026-08-12	$-0.89	$11,578,350	9 / 11
2026-08-13	$-0.88	$21,022,484	8 / 8
2026-08-14	$-0.88	$21,022,484	8 / 8
2026-08-15	$-0.88	$21,022,484	8 / 8
2026-08-16	$-0.88	$21,022,484	8 / 8
2026-08-17	$-0.88	$21,022,484	8 / 8
2026-08-18	$-0.88	$21,022,484	8 / 9
2026-08-19	$-0.88	$21,022,484	8 / 9
2026-08-20	$-0.92	$10,783,122	8 / 9
2026-08-21	$-0.92	$10,783,122	9 / 10
2026-08-22	$-0.92	$10,783,122	9 / 10
2026-08-23	$-0.92	$10,783,122	9 / 10
2026-08-24	$-0.92	$10,783,122	9 / 10
2026-08-25	$-0.93	$10,561,343	9 / 10
2026-08-26	$-0.93	$10,561,343	9 / 10
2026-08-27	$-0.93	$10,561,343	9 / 10
2026-08-28	$-0.93	$10,561,343	9 / 10
2026-08-29	$-0.93	$10,561,343	10 / 11
2026-08-30	$-0.93	$10,561,343	10 / 11
2026-08-31	$-0.93	$10,561,343	10 / 11
2026-09-01	$-0.93	$10,561,343	10 / 11
2026-09-02	$-0.93	$10,561,343	10 / 11
2026-09-03	$-0.93	$10,561,343	10 / 11
2026-09-04	$-0.93	$10,561,343	10 / 11
2026-09-05	$-0.93	$10,561,343	10 / 11
2026-09-06	$-0.93	$10,561,343	10 / 11
2026-09-07	$-0.93	$10,561,343	10 / 11
2026-09-08	$-0.92	$10,561,343	10 / 11
2026-09-09	$-0.92	$10,561,343	10 / 11
2026-09-10	$-0.92	$10,561,343	10 / 11
2026-09-11	$-0.92	$10,561,343	10 / 11
2026-09-12	$-0.92	$10,561,343	10 / 11
2026-09-13	$-0.92	$10,561,343	10 / 11
2026-09-14	$-0.92	$10,561,343	10 / 11
2026-09-15	$-0.92	$10,561,343	10 / 11
2026-09-16	$-0.92	$10,561,343	10 / 11
2026-09-17	$-0.92	$10,561,343	10 / 11
2026-09-18	$-0.92	$10,561,343	10 / 11
2026-09-19	$-0.92	$10,561,343	10 / 11
2026-09-20	$-0.92	$10,561,343	10 / 11
2026-09-21	$-0.92	$10,561,343	10 / 11
2026-09-22	$-0.92	$10,561,343	10 / 11
2026-09-23	$-0.92	$10,561,343	10 / 11
2026-09-24	$-0.92	$10,561,343	10 / 11
2026-09-25	$-0.92	$10,561,343	10 / 11
2026-09-26	$-0.92	$10,545,959	10 / 10
2026-09-27	$-0.92	$10,545,959	10 / 10
2026-09-28	$-0.92	$10,545,959	10 / 10
2026-09-29	$-0.92	$10,545,959	10 / 10
2026-09-30	$-0.92	$10,545,959	10 / 10
2026-10-01	$-0.92	$10,545,959	10 / 10
2026-10-02	$-0.92	$10,545,959	10 / 10
2026-10-03	$-0.92	$10,545,959	10 / 10
2026-10-04	$-0.92	$10,545,959	10 / 10
2026-10-05	$-0.92	$10,545,959	10 / 10
2026-10-06	$-0.92	$10,545,959	10 / 10
2026-10-07	$-0.92	$10,545,959	10 / 10
2026-10-08	$-0.92	$10,545,959	10 / 10
2026-10-09	$-0.92	$11,041,455	10 / 10
2026-10-10	$-0.92	$11,041,455	10 / 10
2026-10-11	$-0.92	$11,041,455	10 / 10
2026-10-12	$-0.92	$11,041,455	10 / 10
2026-10-13	$-0.92	$11,041,455	10 / 10
2026-10-14	$-0.92	$11,041,455	10 / 10
2026-10-15	$-0.92	$11,041,455	10 / 10
2026-10-16	$-0.92	$11,041,455	10 / 10
2026-10-17	$-0.92	$11,041,455	10 / 10
2026-10-18	$-0.92	$11,041,455	10 / 10
2026-10-19	$-0.92	$11,041,455	10 / 10
2026-10-20	$-0.92	$11,041,455	10 / 10
2026-10-21	$-0.92	$11,041,455	10 / 10
2026-10-22	$-0.92	$11,041,455	10 / 10
2026-10-23	$-0.92	$11,041,455	10 / 10
2026-10-24	$-0.92	$11,041,455	10 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	9	4
2026-06-01	10	4
2026-07-01	10	3
2026-08-01	11	3
2026-09-01	11	3
2026-10-01	11	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Fund operations into 2027 with current cashDirect metric needs a verified mapping
Reduce losses and improve EPS trajectoryDiluted EPS: $-0.24 per share
Advance Prime Editing pipeline targeting genetic disorders and cancersDirect metric needs a verified mapping

Next proof point

Nov 6, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.4%Typical daily move · historical

Downside history

-49.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Prime Medicine, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

PRME is a speculative clinical-stage biotechnology company, where the thesis depends on advancing programs rather than established earnings. Its current state is watch: management is progressing toward stated milestones, but recent financial performance trails its industry cohort and risk remains elevated.

What's priced into Prime Medicine, Inc.

The valuation is about 14% above peers, and the case for that premium rests on potential future programs, or optionality, rather than current profits. Model confidence is low, so it is unclear how much of that potential the market assumes; the evidence does not show the full set of conditions that would make valuation fragility concentrated.

What the fundamentals likely do

Near term, results are difficult to assess: the May earnings miss was followed by an in-line August report, while the next report carries a stated risk of guidance cuts. Over the multi-year view, management is advancing PM577a and PM647 toward clinical milestones and aims to submit a BLA, a biologics license application, for PM359 in the first half of 2027; meanwhile, cash and investments fell to $108.8 million by 2026-Q2, with management saying they fund operations into 2027.

What Prime Medicine, Inc. hinges on

The thesis hinges on reaching the planned clinical and regulatory milestones and maintaining enough cash to fund operations into 2027. Near term, guidance cuts or continued weakness in jobs data could add pressure, while stronger results and guidance from healthcare peers could support sector momentum.